Explore new findings on drug-resistant breast cancer and how targeting cell cycle regulators may improve treatment outcomes.

A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Communications , identifies a powerful strategy to overcome drug resistance in ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common ...

Combination therapies represent a promising frontier in cancer treatment, addressing the critical need to enhance efficacy while minimizing resistance. By combining different therapeutic agents and ...

An immunotherapy kept multiple myeloma at bay for over 80 percent of patients in a three-year clinical trial, and the FDA ...

We talked to experts in obesity, tobacco, artificial intelligence, HIV, TB and the NHI to find out what we can expect — and ...

This article was reviewed by Felix Gussone, MD. Key Takeaways: Preventive health focuses on lowering your risk of disease and ...

However, I see one "dark spot" in this acquisition. Merus's operating loss was $110.4 million in Q2, up 82.4% year-over-year, which will ultimately slow Genmab's EPS growth until at least 2028.

AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 ...

Coherus Oncology, Inc. ( CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST Good morning everyone. It's still the morning. Thanks for joining us for another session at ...

The LinkedIn cofounder and frequent Trump target has a simple message for his peers: “Just speak up about the things that you ...